Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice

Fuminori Abe, Akira Matsuda, Mark Schneider, James E. Talmadge

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

The effect of bestatin on hematopoietic parameters and bone marrow progenitor activity (colony-forming unit - granulocyte/macrophage: CFU-GM) was examined in normal and myelosuppressed C57BL/6 mice. CFU-GM frequency and absolute number were determined with a limiting dilution analysis of bone marrow cells in soft agar using recombinant murine colony-stimulating factor - granulocyte/macrophage. We report that bestatin increased splenic, bone marrow, and peripheral blood cellularity and the number of CFU-GM over a dose range from 2.5 mg/kg through 100 mg/kg following i.p., i.v., or oral administration. The greatest myeloid stimulation was observed following multiple injections of bestatin. Bestatin also increased the recovery from cyclophosphamide-induced myelodepression as measured by these parameters. The hematopoietic properties of bestatin following oral administration is of potential importance for clinical application.

Original languageEnglish (US)
Pages (from-to)75-80
Number of pages6
JournalCancer Immunology Immunotherapy
Volume32
Issue number2
DOIs
StatePublished - Mar 1990

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice'. Together they form a unique fingerprint.

  • Cite this